Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Rare diseases, orphan drugs and their regulation: questions and misconceptions

Tambuyzer, Erik · 2010 · Nature Reviews Drug Discovery

Abstract

Sustained advocacy efforts driven by patients' organizations to make rare diseases a health priority have led to regulatory and economic incentives for industry to develop drugs for these diseases, known as orphan drugs. These incentives, enacted in regulations first introduced in the United States in 1983 and later in Japan, Europe and elsewhere, have resulted in substantial improvements in the treatment for patients with a range of rare diseases. However, the advent of orphan drug development has also triggered several questions, from the definition of rarity to the pricing of orphan drugs and their impact on health-care systems. This article provides an industry perspective on some of the common questions and misconceptions related to orphan drug development and its regulation, with the aim of facilitating future progress in the field.

Overview

Integrity signals

Registry

Crossref · 10.1038/nrd3275

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Research works printed but not linked: 5

  1. La Revue Prescire – Enquête. Médicaments pour les maladies rares: bilan contrasté en Europe — Synthèse élaborée collectivement par la Rédaction. La Revue Prescire 26, 781 (2006) (in French).
  2. Hirschhorn, R. & Reuser A. J. J. in The Metabolic & Molecular Bases of Inherited Diseases 8th edn (eds Scriver C. R. et al.) 3395 (McGraw-Hill, New York, 2001).
  3. Genzyme Corporation. Genzyme annual report 2004. (Genzyme, Cambridge, Massachusetts, 2004).
  4. The European Platform for Patients' Organisations, Science and Industry. The 8th workshop on partnering for rare disease therapy development: the reality of orphan medicines. The Platform for Patients' Organisations, Science and Industry website [ online ], (2007).
  5. Commission of the European Communities. Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products. The European Commission website [ online ], (2008).

Cited by

See all 183

Metadata

Authors
Tambuyzer, E.
Corresponding author
Tambuyzer, Erik
Venue
Nature Reviews Drug Discovery
Published
2010-11-09
Volume
9
Issue
12
Pages
921-929
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2019375534
Cited by
182
References
7
Citations by year
2026: 8 · 2025: 5 · 2024: 12 · 2023: 12 · 2022: 13 · 2021: 16 · 2020: 7 · 2019: 11 · 2018: 6 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 15 · 2013: 15 · 2012: 17
FWCI
3.76
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Keywords
rare diseases, orphan drugs, orphan drug regulation, regulatory incentives, drug pricing, health care system impact, patient advocacy, pharmaceutical industry perspective
MeSH terms
Humans, Orphan Drug Production, United States, United States Food and Drug Administration, Drug Approval, Rare Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rare diseases, orphan drugs and their regulation: questions and misconceptions. https://app.cochat.ai/papers/10.1038/nrd3275
The paper
Tambuyzer, E. (2010). Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd3275

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.